CryoLife Reports Record Quarterly Revenues of $28...(row money or raise capital the current a...),Health

Date:7/30/2009

row money or raise capital, the current and future economic crisis may adversely affect our business and financial condition, there are limitations on our use of net operating loss carry-forwards that could result in our inability to use them fully or at all, adverse regulatory action outside of the U.S. could affect our business, physicians have been and may be reluctant to implant or use our preserved tissues or products, our existing insurance policies may not be sufficient to cover our actual claims liability, current economic conditions may impact demand for our tissues and products, intense competition may affect our ability to operate profitably, we may be unable to obtain adequate insurance at a reasonable cost or at all, uncertainties related to patents and protection of proprietary technology may adversely affect the value of our intellectual property, uncertainties related to patents and protection of proprietary technology for products distributed by us may adversely affect our ability to distribute those products, we are dependent on key personnel, we may not be successful in obtaining necessary clinical results and regulatory approvals for products and services in development, and our new products and services may not achieve market acceptance, we may be unable to effectively leverage our existing sales force to sell HemoStase, the lawsuit we filed against Medafor regarding our distribution agreement with Medafor may adversely impact our relationship with Medafor and could hamper or prevent us from distributing HemoStase, rapid technological change could cause our services and products to become obsolete, extensive government regulation may adversely affect our ability to develop and sell products and services, we have experienced operating losses and negative cash flows in the past, and we must continue to address the underlying causes in order to continue to operate profitably and generate positive cash flows, investments in new technologies and acqu
'/>"/>

SOURCE CryoLife, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
2. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
3. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
4. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
5. Cryolife Victim Responds to Untrue Assertions of Cryolife
6. CryoLife Announces Additions to Management Team
7. Gentiva Reports Second Quarter 2009 Results
8. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
9. Encision Reports Profitable First Fiscal Quarter Results
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share